OBJECTIVES: Transapical off-pump mitral valve intervention with neochordae implantation is a novel, minimally invasive procedure for treatment of degenerative mitral valve regurgitation. The aim of this study was to apply control charts (CUSUM curves) to monitor the performance of NeoChord repair during the initial phase of its adoption.
INTRODUCTION
Mitral valve regurgitation (MR) is the second most common heart valve disease in developed countries [1] . Current guidelines on heart valve disease recommend surgery for symptomatic patients presenting with severe MR or asymptomatic MR with incipient impairment of the left ventricular (LV) function [2] . In the last 10 years, the concept of 'respect rather than resect' has gained favour because of its potential superiority in terms of preservation of valvular and ventricle physiology [3] . For this reason, mitral valve repair with chordal implantation has become a widely used treatment option. Degenerative MR is common due to the prolapse or flail of one or both valve leaflets, resulting in poor coaptation. A variety of surgical repair techniques have been developed to restore the leaflet coaptation such as artificial chordae implantation. In the current era of percutaneous procedure advancement, beatingheart artificial neochordae implantation via a transapical approach has received increased attention. The NeoChord procedure is performed using the NeoChord DS1000 Artificial Chordae Delivery System (NeoChord, Inc., St. Louis Park, MN, USA) under 2D and 3D real-time echocardiographic guidance [4, 5] . Initial clinical experience demonstrated a high success rate accompanied by a low rate of complications [6] [7] [8] [9] .
In the present study, we report our experience in acquiring the required surgical skills to perform NeoChord repair by monitoring procedural performance through a time series analysis.
MATERIALS AND METHODS

Study population
Our institution adopted the NeoChord procedure in November 2013. Patients presenting with severe degenerative MR with the prolapse or flail of one or both leaflets were considered candidates for the procedure. Patients with an unfavourable MV anatomy (<3 mm flail overlap of the diseased leaflet with respect to the normal leaflet as suggested by the original company's indication) and/or the presence of active endocarditis were excluded. The surgical indication was based on a discussion between the surgeons and cardiologists considering operative risk profile, clinical and anatomical characteristics and the patient's personal preferences regarding the treatment course.
For the present analysis, we selected only patients who completed the 1-year follow-up (FU). One hundred and twelve patients consecutively treated with the NeoChord repair between November 2013 and March 2016, who completed 1-year FU and who died or underwent MV intervention within the 1st postoperative year were identified from our institutional prospective database. Anatomical classification was applied to describe the MV morphology as follows: 'Type A', isolated central posterior leaflet disease; 'Type B', posterior multisegment disease; 'Type C', anterior and bileaflet disease and 'Type D', paracommissural disease with/without leaflet/annular calcifications.
Operative technique
All procedures were performed by the same surgical team (A.C. and G.G.) in an ordinary cardiac surgery operating room, under general anaesthesia and mechanical ventilation. Transoesophageal echocardiography was performed by the same cardioanaesthesiologist (D.P.). The NeoChord repair procedure has been previously described in detail elsewhere [4, 10] . Briefly, access to the left heart was achieved through a left lateral minithoracotomy in the 5th intercostal space. Two purse-string sutures were placed 2-4 cm posterolateral from the apex of the left ventricle. After ventriculotomy, the NeoChord DS1000 device is inserted in the left ventricle, and 2D and 3D transoesophageal echocardiographic imaging was used to guide the device to the failing leaflet and implant the neochordae. After an appropriate number are implanted, the neochordae were tensioned under direct transoesophageal echocardiographic control until correction of MR was achieved. During this process, systolic blood pressure was maintained between 100 and 120 mmHg with adequate heart volume. Finally, the tensioned neochordae were secured to the LV epicardium using Teflon felt pledgets.
Follow-up examinations
All patients underwent clinical examination and 2D transthoracic echocardiography at 1-, 3-, 6-and 12-month FU. Functional status was assessed according to the New York Heart Association (NYHA) grading, while the residual MR was classified as absent, mild, moderate or severe. MR severity was evaluated using a combination of semi-quantitative (vena contracta width and pulmonary vein flow) and quantitative parameters (regurgitant volume) according to the American Society of Echocardiography guidelines [11] .
Treatment success
A composite end-point was established based on the Mitral Valve Academic Research Consortium (MVARC) definitions [12] . The treatment was considered a success if the patient met the following criteria at the 1-year FU: (i) technical success including the placement of at least 2 neochordae and residual mitral regurgitation < _mild at the end of the procedure; (ii) freedom from major adverse events such as death, stroke, mitral regurgitation >moderate, structural or functional valvular failure and/or unplanned interventions related to the procedure or device at 1 year and (iii) freedom from a decline in baseline symptoms, for example, NYHA functional class > _baseline classification.
Statistical analysis
Cumulative failure charts and their use for monitoring surgical performance have been described previously [13] [14] [15] . In this study, we adopted the statistical principles from the comprehensive tutorial by Rogers et al. [16] to generate a non-risk-adjusted cumulative observed minus expected failure chart. Acceptable event rate (p 0 ) was set at 5%, unacceptable event rate (p 1 ) at 15%, Type I error (a) at 5% and Type II error (b) at 5%. To obtain horizontal control limits, CUSUM was defined as:
where X i indicates the outcome of the operation (X i = 1 if the procedure failed and X i = 0 if the procedure went well) and s was defined as follows:
The upper control boundary (h 1 ) was defined as follows:
The lower control boundary (h 0 ) was defined as follows:
The crossing of the upper boundary (alarm line) was interpreted as an increase of the failure rate to an unacceptable level of p 1 = 15% whereby crossing the lower boundary (reassurance line) led to the conclusion that the failure rate was below the accepted rate of 5%. The curve moving in between the boundary lines indicated lack of statistical significance and triggered further monitoring. Baseline and demographic categorical variables were expressed as percentages, while quantitative variables were expressed as median (1st-3rd quartile). Actuarial curves were obtained by means of the Kaplan-Meier analysis. Statistical analyses were performed using Microsoft Office Excel (Microsoft Corp., Redmond, WA, USA) and SPSS 20.0 (IBM SPSS Statistics, Armonk, NY, USA).
RESULTS
Patient characteristics
Patients' baseline demographic and echocardiographic features are listed in Table 1 . Of note, median age was 68 years, with a relatively low surgical risk profile (median EuroSCORE II 1.25%, median 
Procedural results
Perioperative results are outlined in Table 2 . Procedural success was achieved in 110 (98%) patients. In the 2 technical failure cases, both patients incurred mitral leaflet rupture consequent to the procedure itself and were converted to mitral valve replacement. The median implanted neochordae number was 4 (IQR 3-4), and the median procedure duration time was 118 (IQR 110-155) min. As highlighted in Fig. 1 , the procedure duration remains relatively steady over time (orange line) and increased procedural times seem to be associated with the number of implanted neochordae (blue line) rather than the procedure case number. For this reason, procedural time was not considered in the evaluation of the learning curve.
Postoperative observation revealed prompt recovery of the health status; the median total hospital length of stay was 7 (IQR 6-9) days, and most patients (65%) were discharged home. There were 2 (2%) in-hospital deaths: a 79-year-old high-risk (EuroSCORE II 8.74%) male patient who developed sudden right ventricular failure based on his previously established severe primary pulmonary hypertension associated with severe restrictive pulmonary disease and subsequent cardiac arrest despite a normal functioning repaired mitral valve and an 87-year-old female patient who was considered inoperable due to severe comorbidities and extensive mitral annulus calcifications (EuroSCORE II 5.85%) and who developed early recurrence of severe mitral MR and LV failure. 
One-year results
Of the 108 patients who were discharged, 104 reached the 1st postoperative year. At 1 year, MR was absent in 36 (35%) patients, mild in 40 (38%) patients, moderate in 24 (23%) patients and severe in 4 (4%) patients (Fig. 2) . Four patients underwent MV reintervention due to recurrent MR. The overall failure rate at 1-year FU was 11% (12 of 112 patients). Causes of recurrent severe MR are listed in Table 3 . At 1-year FU, treatment success was achieved in 89.3 ± 2.9% of patients (Fig. 3) .
Learning curve analysis
The actual probability of the failure chart depicts 3 phases of experience: an initial 'learning phase' (first 20 procedures), a second 'intermediate phase' and a final 'expert phase'. The 'learning phase' is characterized by a relatively high actual probability of failure (25%), while the 'expert phase' demonstrated a decrease in failure probability to 5% (Fig. 4) . The institutional CUSUM curve shows a flat pattern for the first 20 patients, which moved between the boundary lines, reflecting the 'learning phase' described above (Fig. 5) . Subsequently, the curve begins to trend downwards, but it generally remains above the reassurance line. After the 49th procedure, the curve turns sharply downwards and remains below the reassurance line, reflecting the 'expert phase'.
DISCUSSION
MV repair has been established as the surgery of choice for patients with severe degenerative MR [2] . Repair techniques have undergone several significant advancements since Frater performed the first repair in the mid-1960s [17] , with the advent of the French correction technique by Carpentier in the early 1980s [18] , and again in the 1990s with the introduction of chordal replacement by Frater et al. [19] . Individual repair techniques have also been incrementally modified, simplified and then applied (cit. Denton Cooley). This development has been possible primarily due to the growing wealth of knowledge of the MV physiology together with the acquisition of echocardiographic methods leading to a logarithmic increase in the annual number of MV repair procedures performed. It is evident that this wide adoption of MV repairs has led to the standardization of the procedure with consequent reduction of the learning curve required to perform it [20] .
Minimally invasive approaches for heart valve surgery have become increasingly popular over the past decade. These approaches lead to less pain, shorter hospital stays, faster return to normal activities and potential cost savings [21] . The NeoChord procedure is a new surgical technique that encompasses these goals and, moreover, avoids the use of cardiopulmonary bypass and cardioplegic arrest. However, this technique requires a new type of surgical and echocardiographic dexterity to be performed successfully [4] . Surgeons attempting this technique must leave old preconceptions about the traditional MV surgery behind and be open to developing a new skill set for MV repair. For example, the NeoChord procedure requires a significant eye-hand coordination, visually guided reaching, grasping and object manipulation, together with the ability to visually decipher 2D and 3D echocardiographic details and finely coordinate motor responses of the eye and hand to produce controlled, rapid and accurate movements in a beating environment.
Our institution was the first to adopt the NeoChord procedure on a routine basis, and, since November 2013, we have performed 165 of the 730 cases completed worldwide, a quarter of the total experience. Our early adoption has provided us with the 
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opportunity to play a pivotal role in refining several technical aspects of the procedure (posterolateral ventricular access, patientspecific modifications based on the MV morphology, single pledget fixation, tensioning protocol with tourniquets and overtensioning), standardizing the echocardiographic guidance protocol as well as establishing patient selection criteria (leafletto-annulus index and MV morphological classification). We previously reported early efficacy and safety of the NeoChord procedure [6] [7] [8] [9] 22] , but this is the first study methodologically focused on the impact of our pioneering efforts on procedural outcomes. Whenever a new technique is introduced, surgeons acquire expertise and experience directly in the field. Thus, they undergo a 'learning curve' and, unfortunately, their patients may be at higher risk during this period. The CUSUM charts have the advantage of accounting for time as a variable in clinical trials, while avoiding the problem of repeat significance tests, and controlling the process in real time while learning. Trend analysis, whether for a declining or improving trend, provides a process to identify the cause of the change. The use of the CUSUM charts in cardiac surgery was first introduced by De Leval et al. [23] to monitor surgical performance in paediatric cardiac surgery. After their study, several authors recognize the utility of the CUSUM method to assess the learning curve [24] .
After a literature review, we observed that large, consecutive, minimally invasive MV surgery series considered an acceptable failure rate of 10-15% in the early postoperative period [25, 26] . Thus, for this study, we decided to set the acceptable event rate at more restrictive 5% and the unacceptable event rate at 15%. Additionally, we decided to extend the observation time up to the 1st postoperative year to maintain a high level of criticism on the procedure. However, we recognize that these boundaries are arbitrary, as no benchmark results for minimally invasive MV surgery (and for theNeoChord repair) are available.
The most important findings of the present study are the following. First, we confirm that the NeoChord procedure is safe and effective; the alarm line was never crossed, not even at the beginning of the experience. Moreover, most of the early failures were due to technical errors during the crossing of the MV, which were subsequently avoided with the improvement of the Second, the probability of failures changed over time according to a 3-phase pattern. The first phase coincided with the first 20 cases; in this phase, the risk of failure was dependent on the standardization of the technique. For the NeoChord procedure, the correct selection of the ventricular access site for the instrument and the correct tensioning of the neochordae have proved to be crucial [27] . Moreover, as the surgical and echocardiographic techniques employed were beyond those used in the traditional surgical MV repair, the initial NeoChord repair cases required proctoring to guide the entire surgical team. In the 2nd phase, the surgeon started to handle procedures independently and became more confident with the device and with 3D echocardiographic guidance. The 3rd phase began after the surgeon had completed 50 cases and their technique had been established. Furthermore, the 3rd phase also coincided with a refinement in patient selection criteria (anatomical classification, leaflet-to-annular index and coaptation index) [28] . This last phase is a period of good performance [29, 30] . It is important to underline that this is the complex and multidisciplinary learning curve of a team that approached a completely new procedure by understanding and developing not only specific technical skills but also a new communication code.
Considering the previously described procedure standardization that occurred during the early experience at our institution, it is reasonable to believe that significantly fewer cases will be required to learn the NeoChord repair technique by beginners going forward. In addition, the learning curve will be improved by other variables: (i) more experienced proctors, (ii) establishment of a training programme using a biosimulator (ex vivo pulsatile heart model) and a pneumatic simulator and (iii) greater familiarity with advanced imaging. Future studies are warranted to assess the evolution of the learning curve after a wide adoption of the technique across European and North American centres.
Interestingly, a CUSUSM subanalysis only of the Type A morphologies demonstrated that the number of cases required to become expert with the procedures was 11, confirming that the morphological complexity of the valve plays a role in the learning process of the procedure. This subanalysis is mentioned with a word of caution because it is biased by the fact that the CUSUM methodology should be applied only for consecutive cases and not for mixed study population subanalysis as it was here.
CONCLUSION
In conclusion, NeoChord repair is a safe and reproducible procedure that can be performed with low mortality and morbidity. Learnings from the early experience led to significant technique refinements and standardization; however, due to the novelty of the approach, there remains a learning curve associated with the acquisition of new surgical skills and familiarization with a new set of guidelines. Surgeons, cardiologists and anaesthesiologists who want to start a NeoChord repair programme should have a structured period of training as a unique team at institutions that perform a large number of these operations per year, together with dedicated training using simulators. Control charts may provide an understandable and up-to-date overview that allows the detection of trends and can encourage local investigation and help to maintain a high standard of care in the adoption of innovative cardiac procedures.
